ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

BENLYSTA
Miscellaneous immune disorders
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

BENLYSTA Rx

Generic Name and Formulations:
Belimumab 120mg/vial, 400mg/vial; pwd for IV infusion after reconstitution and dilution; 200mg/mL prefilled autoinjector or syringe; soln for SC inj; preservative-free.

Company:
GlaxoSmithKline

Therapeutic Use:

Indications for BENLYSTA:

Systemic lupus erythematosus, in adults with active, autoantibody-positive SLE on standard therapy. Limitations of use: not evaluated in severe active lupus nephritis or CNS lupus.

Adult:

For IV regimen (use vials only): give over 1hr; slower if infusion reaction occurs. 10mg/kg every 2 weeks for 3 doses, then 10mg/kg every 4 weeks. May consider premedication for infusion/hypersensitivity reactions prior to initiation. For SC regimen (use prefilled autoinjector or syringe only): 200mg once weekly in the abdomen or thigh. Transitioning from IV to SC: give first SC dose 1–4 weeks after last IV dose.

Children:

Not established.

Warnings/Precautions:

More deaths reported with Benlysta than placebo in clinical trials. Supervise infusion; have resuscitative equipment and trained personnel available in case of infusion/hypersensitivity reactions. Severe or chronic infections; consider interrupting if new infections develop during treatment and monitor closely. Evaluate if new-onset or deteriorating neurological signs/symptoms develop; discontinue if progressive multifocal leukoencephalopahy (PML) is confirmed. Monitor for malignancies, depression or other mood changes. Elderly. Black/African American. Pregnancy. Females of reproductive potential should use effective contraception during and for ≥4mos after last dose. Nursing mothers.

Interactions:

Concomitant with other biologics, IV cyclophosphamide: not recommended. Immunizations (may get suboptimal response); avoid live vaccines for 30 days prior to and during treatment.

Pharmacological Class:

Human IgG1gamma monoclonal antibody.

Adverse Reactions:

Nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis; serious infections (may be fatal), PML, malignancies, infusion and/or hypersensitivity reactions.

Note:

To register pregnant women exposed to Benlysta call (877) 681-6296.

Generic Availability:

NO

How Supplied:

Single-dose vial (120mg in 5mL, 400mg in 20mL)—1; single-dose prefilled autoinjector (200mg/mL)—4 (w. needle); single-dose prefilled syringe (200mg/mL)—4 (w. needle)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs